Project Grant R01CA293654
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$636K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $678,399 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of Texas MD Anderson Cancer Center. The funding will support a research study to evaluate the impact of a prebiotic diet intervention combined with standard immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma.
The study aims to investigate whether the prebiotic diet intervention can modulate the...
This federal Project Grant award, valued at $154,568 and awarded by the National Cancer Institute (NCI), will support research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The research aims to enhance understanding of how ILC3s modulate adaptive immune responses, which could inform novel combination treatment strategies to improve the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This $673,526 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to the University of Pittsburgh. The award will fund research aimed at understanding the role of zinc metabolism in therapy-resistant melanoma, particularly in tumors with low expression of the p16 protein.
The key objectives are to: 1) Investigate how p16 loss leads to increased zinc transporter SLC39A9 expression, which depletes zinc in the tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to Baylor College of Medicine to conduct research investigating intratumoral microbiota and immune predictors of response to immunotherapy in lung cancer. The key objectives are to:
Identify intratumoral microbiome profiles predictive of response to immune checkpoint inhibitor (ICI) therapy, using whole-metagenome sequencing.
Characterize spatial immune signatures...
This $127,049.00 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to define the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. Specifically, the project will:
Generate patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells needed to exert immune pressure on a heterogeneous tumor like...
This $530,612 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to investigate the role of the gut microbiome in melanoma progression and prevention of lymph node metastasis. The key research objectives are to: 1) Identify gut microbial and immunologic features associated with tumor progression and lymph node metastasis in melanoma patients, and 2) Determine strategies to modulate the gut microbiome to prevent melanoma progression and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Chicago focused on developing genetically-engineered Bifidobacterium bacteria to overcome therapy resistance in metastatic pancreatic ductal adenocarcinoma. The $581,087 award, effective July 1, 2024 through June 30, 2029, will investigate administering the engineered Bifidobacterium to deliver a novel human IL-2 protein to the tumor...
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $176,712 to the University of Pittsburgh to support research on co-stimulation of T cell responses to nascent, emerging tumors. The key objectives are to develop a new mouse model to investigate the role of the CD91 receptor in providing co-stimulation and cytokines that are essential for priming T cell responses against emerging cancer cells. This...